Superseded public profile

Not FDA-approved↗Safety records↗

Superseded · version 1: LL-37↗↗

Related names recorded in this version: Cathelicidin LL-37, Ropocamptide↗

A 37-amino-acid human cathelicidin peptide, also called ropocamptide, that FDA lists among compounding substances that may present significant safety risks.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.

What this version reported

FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

LL-37 is a 37-amino-acid peptide of the human cathelicidin family, recorded in FDA’s substance registry as cathelicidin LL-37 (human), with the international name ropocamptide.1 FDA lists cathelicidin LL-37 among compounding substances that may present significant safety risks. It states that it lacks enough safety information to know whether LL-37 would cause harm in people.2 FDA also notes nonclinical findings suggesting harm to male reproduction and that LL-37 can promote tumors in some tissues. No FDA approval is reported in the sources reviewed here, and LL-37 is not among the six peptides in HHS’s October 2026 draft policy.2,4

At a glance

What it is
A 37-amino-acid peptide beginning with two leucines (hence LL-37), recorded as human cathelicidin LL-37 and ropocamptide in FDA’s substance registry.1
FDA status
No FDA approval is reported in the sources reviewed here. FDA lists cathelicidin LL-37 among bulk substances whose compounding nominations were withdrawn and that may present significant safety risks.2
Human evidence
FDA states that it lacks sufficient safety information for LL-37 in people. The FDA sources reviewed here describe only nonclinical research findings.2
Evidence strength
Animal and lab studies only

What is LL-37?

LL-37 is a peptide of 37 amino acids, starting with two leucines, that FDA’s substance registry records as cathelicidin LL-37 (human) and under the international nonproprietary name ropocamptide.1

How is LL-37 thought to work?

The FDA sources reviewed here do not describe how LL-37 works. They report nonclinical findings on its possible harms rather than its intended effects.1,2

What do human studies show?

FDA states that it lacks sufficient safety-related information on cathelicidin LL-37 to know whether it would cause harm when given to humans.2

The FDA sources reviewed here do not describe human trials of LL-37 or evaluate whether it is effective for any use.2

What the evidence base contains

  • Animal or laboratory research Nonclinical research findings, cited by FDA, suggesting harmful effects on male reproduction and that LL-37 can promote tumor growth in some tissues.2

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is LL-37 FDA-approved?

None of the sources reviewed here reports an approval of LL-37 by FDA.1,2

FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.2

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. LL-37 is not among them.3,4

Timeline

  1. FDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns.2

What is still unknown?

Whether it is safe in people, which FDA states it lacks the information to judge.2

Whether the reproductive and tumor-promoting effects seen in nonclinical research apply to people.2

Sources for this version

  1. 1
    Ropocamptide (cathelicidin LL-37, human) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026